PREVENT PRECLINICAL DRUG DEVELOPMENT PROGRAM: PRECLINICAL EFFICACY AND INTERMEDIATE BIOMARKERS (POP: 1/25/2019 - 1/24/2024)
$3,500N01FY2019CANIH
University Of Tx Md Anderson Can Ctr, Houston TX
Investigators
Abstract
The purpose of this task order is to hold an orientation/kickoff meeting to discuss Standard Operating Procedures (SOP) for all Contractors awarded an Indefinite Delivery, Indefinite Quantity (ID/IQ) contract for the PREVENT Cancer Preclinical Drug Development Program.
View original record on NIH RePORTER →